CAS 210829-30-4|Gemcitabine elaidate

Introduction：Basic information about CAS 210829-30-4|Gemcitabine elaidate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Gemcitabine elaidate BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Gemcitabine elaidate
CAS Number	210829-30-4	Molecular Weight	527.644
Density	1.2±0.1 g/cm3	Boiling Point	631.4±65.0 °C at 760 mmHg
Molecular Formula	C₂₇H₄₃F₂N₃O₅	Melting Point	/
MSDS	/	Flash Point	335.7±34.3 °C

Names

Name	[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate
Synonym	More Synonyms

Gemcitabine elaidate BiologicalActivity

Description	Gemcitabine elaidate(CP-4126; CO-101) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.IC50 value:Target: Gemcitabine analogUpon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5'-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase. Check for active clinical trials or closed clinical trials using this agent.
Related Catalog	Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Cell Cycle/DNA Damage >>Nucleoside Antimetabolite/AnalogResearch Areas >>Cancer

Description

Gemcitabine elaidate(CP-4126; CO-101) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.IC50 value:Target: Gemcitabine analogUpon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5'-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase. Check for active clinical trials or closed clinical trials using this agent.

Related Catalog

Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Cell Cycle/DNA Damage >>Nucleoside Antimetabolite/AnalogResearch Areas >>Cancer

Chemical & Physical Properties

Density	1.2±0.1 g/cm3
Boiling Point	631.4±65.0 °C at 760 mmHg
Molecular Formula	C₂₇H₄₃F₂N₃O₅
Molecular Weight	527.644
Flash Point	335.7±34.3 °C
Exact Mass	527.317078
PSA	117.66000
LogP	7.70
Vapour Pressure	0.0±4.2 mmHg at 25°C
Index of Refraction	1.536
InChIKey	HESSNRGIEVBPRB-QDDPNBLJSA-N
SMILES	CCCCCCCCC=CCCCCCCCC(=O)OCC1OC(n2ccc(N)nc2=O)C(F)(F)C1O
Storage condition	2-8℃

Synonyms

Gemcitabine elaidate [INN]

2'-Deoxy-2',2'-difluoro-5'-O-[(9E)-9-octadecenoyl]cytidine

CO-101

UNII-231C73W7LG

Gemcitabine elaidate

CP-4126

Gemcitabine elaidate (USAN/INN)

Cytidine, 2'-deoxy-2',2'-difluoro-5'-O-[(9E)-1-oxo-9-octadecen-1-yl]-

Gemcitabine (elaidate)

Recommended......